Full Text
EE561 Is Lecanemab Worth the Wait? Real Option Value and the Cost of Future Innovation in Alzheimer's Disease

Abstract

Authors

Juliana Paiva Kevin D. Davina Frick Emmanuel Fulgence Drabo

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×